Get the Stockscreener App
11.31
5.55%
0.595
Rapt Therapeutics Inc stock is traded at $11.31, with a volume of 34,525.
It is up +5.55% in the last 24 hours and down -7.86% over the past month.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
See More
Previous Close:
$10.72
Open:
$10.77
24h Volume:
34,525
Relative Volume:
0.30
Market Cap:
$187.13M
Revenue:
$3.25M
Net Income/Loss:
$-116.80M
P/E Ratio:
-3.7098
EPS:
-3.05
Net Cash Flow:
$-98.17M
1W Performance:
-3.62%
1M Performance:
-7.86%
6M Performance:
+13.15%
1Y Performance:
-38.51%
1-Day Range:
$10.67
$11.31
1-Week Range:
$10.06
$12.25
52-Week Range:
$5.6652
$26.56
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Name
Rapt Therapeutics Inc
Sector
Industry
Phone
(650) 489-9000
Address
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Compare RAPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
11.31 | 193.99M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Upgrade | JP Morgan | Underweight → Neutral |
| May-22-25 | Resumed | H.C. Wainwright | Buy |
| Dec-26-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-13-24 | Downgrade | Stifel | Buy → Hold |
| Nov-11-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-14-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-10-24 | Downgrade | Barclays | Overweight → Equal Weight |
| May-10-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-22-24 | Downgrade | UBS | Buy → Neutral |
| Feb-21-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-21-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-21-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-20-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-16-24 | Initiated | Evercore ISI | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Sep-14-23 | Initiated | Berenberg | Buy |
| Aug-09-23 | Initiated | Stifel | Buy |
| Jun-15-23 | Initiated | Barclays | Overweight |
| Jan-04-23 | Initiated | Guggenheim | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | CapitalOne | Overweight |
| May-24-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-09-21 | Initiated | JP Morgan | Overweight |
| Aug-12-21 | Initiated | SVB Leerink | Outperform |
| Jun-21-21 | Initiated | Piper Sandler | Overweight |
| Jun-01-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-13-20 | Initiated | ROTH Capital | Buy |
| Nov-25-19 | Initiated | BMO Capital Markets | Outperform |
| Nov-25-19 | Initiated | UBS | Buy |
| Nov-25-19 | Initiated | Wells Fargo | Outperform |
View All
Rapt Therapeutics Inc Stock (RAPT) Latest News
Backtesting results for RAPT Therapeutics Inc. trading strategiesJobs Report & Free AI Powered Buy and Sell Recommendations - Newser
Can momentum traders help lift RAPT Therapeutics Inc.Analyst Downgrade & Real-Time Buy Signal Alerts - Newser
Is RAPT Therapeutics Inc. building a consolidation baseEntry Point & Daily Oversold Bounce Ideas - Newser
Reversal indicators forming on RAPT Therapeutics Inc. stockPortfolio Update Report & Precise Buy Zone Identification - Newser
Trend analysis for RAPT Therapeutics Inc. this weekCEO Change & Low Risk High Win Rate Stock Picks - Newser
Using AI based signals to follow RAPT Therapeutics Inc.2025 Dividend Review & Free Daily Entry Point Trade Alerts - Newser
How to read the order book for RAPT Therapeutics Inc.2025 Key Highlights & Safe Entry Zone Tips - Newser
Can machine learning forecast RAPT Therapeutics Inc. recoveryJuly 2025 Volume & Community Consensus Picks - Newser
Earnings visualization tools for RAPT Therapeutics Inc.2025 Sector Review & Consistent Profit Trading Strategies - Newser
How hedge fund analytics apply to RAPT Therapeutics Inc. stockWeekly Investment Recap & Technical Analysis for Trade Confirmation - Newser
Volatility clustering patterns for RAPT Therapeutics Inc.2025 Risk Factors & Consistent Growth Equity Picks - Newser
How to forecast RAPT Therapeutics Inc. trends using time series2025 Momentum Check & Daily Stock Trend Reports - Newser
How to interpret RSI for RAPT Therapeutics Inc. stock2025 Growth vs Value & Free Risk Controlled Daily Trade Plans - Newser
Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 101.02%: Read This Before Placing a Bet - Nasdaq
Using Ichimoku Cloud for RAPT Therapeutics Inc. technicalsEarnings Overview Summary & Weekly Sector Rotation Insights - Newser
Applying Elliott Wave Theory to RAPT Therapeutics Inc.Dividend Hike & Real-Time Stock Movement Alerts - Newser
Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Will RAPT Therapeutics Inc. outperform tech stocksJuly 2025 Trends & Daily Risk Controlled Trade Plans - thegnnews.com
Understanding RAPT Therapeutics Inc.’s price movement2025 Market Sentiment & Fast Moving Market Watchlists - Newser
Has RAPT Therapeutics Inc. formed a bullish divergenceJuly 2025 Highlights & Entry Point Confirmation Signals - Newser
RAPT Therapeutics Inc. Recovery Likely Here’s What Data ShowsMarket Sentiment Review & Daily Price Action Insights - beatles.ru
RAPT Therapeutics Inc. stock daily chart insightsMarket Volume Report & Low Drawdown Momentum Trade Ideas - Newser
RAPT Therapeutics Inc. Builds Base for Possible Rebound2025 Analyst Calls & Fast Entry High Yield Tips - beatles.ru
What high frequency data says about RAPT Therapeutics Inc.2025 Price Momentum & Weekly Hot Stock Watchlists - Newser
Building trade automation scripts for RAPT Therapeutics Inc.2025 Market Overview & Smart Investment Allocation Insights - Newser
Sentiment analysis tools applied to RAPT Therapeutics Inc.Free Profit Target Stock Opportunity Monitor - Newser
Why RAPT Therapeutics Inc. stock attracts strong analyst attentionLow Cost High Gain Picks - newsyoung.net
RAPT Therapeutics: UBS maintains Neutral, raises PT to $9 from $8. - AInvest
Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross - Yahoo Finance
Will RAPT Therapeutics Inc. continue its uptrendSector Rotation and Stock Opportunity Analysis - Newser
Volume spikes in RAPT Therapeutics Inc. stock – what they meanFree Smart Trade Plans With Risk Protection - Newser
Analyzing drawdowns of RAPT Therapeutics Inc. with statistical toolsAlgorithmic Forecast for Swing Trading Picks - Newser
Rapt Therapeutics (NASDAQ:RAPT) Cut to Sell at Wall Street Zen - Defense World
Historical volatility pattern of RAPT Therapeutics Inc. visualizedRisk Aware Trading Ideas with Alert Levels - Newser
Promising Potential of RAPT Therapeutics’ RPT904 Drives Buy Rating - TipRanks
HC Wainwright Issues Positive Forecast for RAPT Earnings - Defense World
Ranking RAPT Therapeutics Inc. among high performing stocks via toolsSmart Swing Picks with Confirmed Signals - Newser
Multi asset correlation models including RAPT Therapeutics Inc.Technical Insight Guide for Safer Trades - Newser
Published on: 2025-08-09 04:24:12 - beatles.ru
Rapt Therapeutics Inc Stock (RAPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):